ValiRx (LSE:VAL) has reinforced the intellectual property position of its majority-owned subsidiary Cytolytix after securing a key European patent covering nanoparticles designed for anti-cancer peptides, licensed from King’s College London. The patent strengthens Cytolytix’s underlying technology platform, improves its appeal to prospective investors, and broadens potential opportunities for licensing agreements and strategic oncology partnerships.
The group has also submitted a new patent application covering second-generation liposomal versions of its oncolytic peptide technology. The filing is supported by preclinical research demonstrating immunogenic cell death in triple negative breast cancer models. In parallel, the company continues to progress a separate core European patent while presenting the technology platform to industry participants. ValiRx said it is engaged in discussions with several prospective partners, including a major pharmaceutical company, and intends to expand use of the oncolytic platform across both human oncology and its Animal Health division.
ValiRx plc’s outlook continues to be weighed by difficult financial performance, including ongoing losses and dependence on external funding. Technical indicators point to a generally bearish trend in the shares, although there remains some potential for upward price movement. Valuation metrics remain weak, reflecting a negative price-to-earnings ratio and the absence of a dividend yield.
More about ValiRx plc
ValiRx plc (LSE:VAL) is a London-listed life sciences business focused on developing early-stage cancer therapeutics and women’s health treatments. The company provides scientific, commercial and financial support frameworks aimed at advancing novel drug candidates into clinical development. Through its subsidiary structure, ValiRx develops promising preclinical assets before seeking licensing agreements or strategic partnerships for further development and commercialisation.
Leave a Reply